Vertex Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Vertex Pharmaceuticals Inc Unternehmen

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Vertex Pharmaceuticals Inc Informationen



BörsenkürzelVRTX

Name des UnternehmensVertex Pharmaceuticals Inc

IPO-datumJul 24, 1991

CEOKewalramani (Reshma)

Anzahl der mitarbeiter6100

WertpapierartOrdinary Share

GeschäftsjahresendeJul 24

Addresse50 Northern Avenue

StadtBOSTON

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl02210

Telefon16173416393

Websitehttps://www.vrtx.com/

BörsenkürzelVRTX

IPO-datumJul 24, 1991

CEOKewalramani (Reshma)

Führungskräfte von Vertex Pharmaceuticals Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

90.67K

+38857.00%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+5000.00%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

44.00K

+11333.00%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

33.48K

+9012.00%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

33.05K

+7249.00%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

24.37K

+9068.00%

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

22.93K

+6800.00%

Mr. Lloyd A. Carney

Independent Director

6.32K

-800.00%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.57K

-266.00%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+796.00%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

90.67K

+38857.00%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+5000.00%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

44.00K

+11333.00%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

33.48K

+9012.00%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

33.05K

+7249.00%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

24.37K

+9068.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

TRIKAFTA

2.65B

86.26%

ALYFTREK

247.00M

8.03%

Other CF products

175.80M

5.71%

Nach RegionUSD

Name

Umsatz

Anteil

United States

1.98B

64.24%

Europe

836.90M

27.20%

Other

263.20M

8.56%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

TRIKAFTA

2.65B

86.26%

ALYFTREK

247.00M

8.03%

Other CF products

175.80M

5.71%

Aktionärsstatistik

Aktualisiert: Sat, Nov 15

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.45%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

Andere

63.53%

Aktionäre

Anteil

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.45%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

Andere

63.53%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

60.46%

Investment Advisor/Hedge Fund

27.86%

Pension Fund

2.37%

Research Firm

2.35%

Bank and Trust

2.10%

Sovereign Wealth Fund

1.50%

Hedge Fund

1.14%

Individual Investor

0.19%

Insurance Company

0.06%

Andere

1.96%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

2986

248.55M

97.96%

-4.86M

2025Q3

2933

249.27M

98.24%

-2.14M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Capital World Investors

25.91M

10.21%

-2.82M

-9.82%

Sep 30, 2025

The Vanguard Group, Inc.

24.10M

9.5%

+240.67K

+1.01%

Sep 30, 2025

Capital Research Global Investors

16.55M

6.52%

+444.99K

+2.76%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

14.47M

5.7%

+317.50K

+2.24%

Sep 30, 2025

State Street Investment Management (US)

11.61M

4.57%

-169.23K

-1.44%

Sep 30, 2025

Geode Capital Management, L.L.C.

5.97M

2.35%

+45.00K

+0.76%

Sep 30, 2025

Invesco Capital Management (QQQ Trust)

5.69M

2.24%

+318.09K

+5.92%

Dec 31, 2025

Wellington Management Company, LLP

4.77M

1.88%

-41.34K

-0.86%

Sep 30, 2025

Capital International Investors

4.69M

1.85%

+2.05M

+77.89%

Sep 30, 2025

AllianceBernstein L.P.

4.52M

1.78%

+144.27K

+3.30%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Fri, Dec 5

Name

Anteil

VanEck Biotech ETF

9.71%

ProShares Ultra Nasdaq Biotechnology

8.83%

Invesco Nasdaq Biotechnology ETF

8.76%

iShares Biotechnology ETF

7.43%

Invesco Biotechnology & Genome ETF

5.35%

Natixis Loomis Sayles Focused Growth ETF

4.48%

First Trust NASDAQ Pharmaceuticals ETF

4.23%

First Trust NYSE Arca Biotechnology Index Fund

3.5%

Franklin Genomic Advancements ETF

3.33%

Simplify Health Care ETF

3.25%

VanEck Biotech ETF

Anteil9.71%

ProShares Ultra Nasdaq Biotechnology

Anteil8.83%

Invesco Nasdaq Biotechnology ETF

Anteil8.76%

iShares Biotechnology ETF

Anteil7.43%

Invesco Biotechnology & Genome ETF

Anteil5.35%

Natixis Loomis Sayles Focused Growth ETF

Anteil4.48%

First Trust NASDAQ Pharmaceuticals ETF

Anteil4.23%

First Trust NYSE Arca Biotechnology Index Fund

Anteil3.5%

Franklin Genomic Advancements ETF

Anteil3.33%

Simplify Health Care ETF

Anteil3.25%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten